

#3  
FPT  
M/DMY

jc:525 U.S. PTO  
08/993962  
12/18/97



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No.: 2813-K

LYMAN, Stewart D. and BECKMANN, M. Patricia

Serial No.:	--to be assigned--	Art Unit:	Unknown
Filed:	December 18, 1997	Examiner:	Unknown
For:	METHODS OF USING FLT-3-LIGAND		

## BOX SEQUENCE

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 2023

### INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR 1.56, 1.97 and 1.98, and in addition to the documents already listed on the Information Disclosure Statement in parent applications, applicant provides the following documents for consideration by the examiner during the examination of the above-captioned application. The documents are listed on the attached Form PTO-1449, and copies of each are provided for the convenience of the examiner.

Applicant wishes to bring the attention of the examiner to the following copending applications:

- 1) USSN 08/444,627 which discloses and claims hematopoietic cell expansion media comprising flt3-ligand in combination with another cellular growth factor.
- 2) USSN 08/399,404 which discloses and claims extracorporeal cell culture and transplantation kits, comprising flt3-ligand. The instant application is a continuation of application USSN 08/399,404.
- 3) USSN 08/738,628, which discloses and claims an extracorporeal cell culture composition comprising flt3-ligand plus thrombopoietin.


Further, applicant wishes to bring the following documents to the attention of the examiner:

- 4) deVries et al., *Exp. Hematology*, vol. 22(8):724 (1994) abstract #174.
- 5) Small, D. et al., *PNAS*, vol. 91(2):459 (1994)
- 6) Zeigler et al., *Blood*, 84(8):2422 (1994)
- 7) deVries et al., *Blood*, 84(10), Suppl. 1, p. 279a, (1994) abstract #1100
- 8) Hannum et al., *Nature*, 368:643 (1994)

- 9) Broxmeyer et al., *Blood Cells*, 20(2-3):492 (1994)
- 10) deVries et al., *J. of Cell Biochem.*, Suppl. 18B, p. 177, (1994) abstract #H100
- 11) Rossner et al., *Cell Growth & Differentiation*, 5(5):549 (1994)
- 12) U.S. Patent No. 5,399,493, Emerson et al.
- 13) U.S. Patent No. 5,453,357, Hogan
- 14) U.S. Patent No. 5,397,706, Correa et al.
- 15) U.S. Patent No. 5,459,069, Palsson et al.
- 16) U.S. Patent No. 5,437,994, Emerson et al.
- 17) U.S. Patent No. 5,061,620, Tsukamoto et al.
- 18) U.S. Patent No. 5,283,354, Lemischka
- 19) U.S. Patent No. 5,554,512, Lyman et al.
- 20) U.S. Patent No. 5,548,065, Lemischka
- 21) U.S. Patent No. 5,270,459, Lemischka
- 22) U.S. Patent No. 5,367,057, Lemischka
- 23) U.S. Patent No. 5,525,708, Nocka et al.
- 24) WO 93/0826, Heimfeld et al.
- 25) EP 627487, Lyman et al.
- 26) Stewart et al., *Blood*, 81:2283 (1993)
- 27) U.S. Patent No. 5,326,558, Turner et al.

Since the submission of the documents listed on the Form PTO-1449 is made before the mailing of the first Office Action in connection with the above-captioned application, no fee under 37 CFR 1.17(p) is believed to be required. However, should it be determined that a fee is necessary, applicants authorize the Commissioner to charge applicants' deposit account no. 09-0089 in an amount necessary to permit consideration of this Information Disclosure Statement.

Respectfully submitted,



Stephen L. Malaska  
Attorney for Applicants  
Reg. No. 32,655

Immunex Corporation  
51 University Street  
Seattle, Washington 98101  
Telephone (206) 587-0430

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX SEQUENCE, Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date indicated below.

Date: Dec. 18, 1997

Signed: Francis M. Kertoon